PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes

Diabetes Care

Volumn 42, Issue 9, 2019, Pages 1724-1732

  Aroda, Vanita R ^a,b   Rosenstock, Julio ^c   Terauchi, Yasuo ^d   Altuntas, Yuksel ^e   Lalic, Nebojsa M ^f   Villegas, Enrique C Morales ^g   Jeppesen, Ole K ^h   Christiansen, Erik ^h   Hertz, Christin L ^h   Haluzík, Martin ⁱ  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c Dallas Diabetes and Endocrine Center at Medical City   (United States)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

^e UNIVERSITY OF HEALTH SCIENCES   (Turkey)

^f UNIVERSITY OF BELGRADE   (Serbia)

^g Aguascalientes Cardiometabolic Research Center   (Mexico)

^h NOVO NORDISK A S   (Denmark)

ⁱ INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; PLACEBO; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY WEIGHT CHANGE; BODY WEIGHT LOSS; CONTROLLED STUDY; DECREASED APPETITE; DIABETIC DIET; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFLUENZA; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; BLOOD; DIET; DRUG EFFECT; EXERCISE; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; DIABETES MELLITUS, TYPE 2; DIET; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; GLUCAGON-LIKE PEPTIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; WEIGHT LOSS;

EID: 85068231385     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc19-0749     Document Type: Article

References (25)

1. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetesd2018. Diabetes Care 2018;41(Suppl. 1):S73-S85
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-442
3. U. S. FoodandDrug Administration. Ozempic-Highlights of prescribing information [Internet], 2017. Available from https://www. accessdata. fda. gov/drugsatfda_docs/label/2017/ 209637lbl. pdf. Accessed 14 November 2018
4. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844
5. Graaf Cd, Donnelly D, Wootten D, et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev 2016;68: 954-1013
6. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 2003;20:153-214
7. Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA 2017;318:1460-1470
8. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 2018;10:eaar7047
9. Granhall C, Donsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet 2019;58:781-791
10. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191-2194
11. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1), Step 4 [Internet], 1996. Available from https://www. ich. org/fileadmin/Public_Web_Site/ICH_Products/ Guidelines/Efficacy/E6/E6_R1_Guideline. pdf. Accessed 14 November 2018
12. Aroda VA, Saugstrup T, Buse JB, DonsmarkM, Zacho J, Davies MJ. Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example. Diabetes Obes Metab. 5 June 2019 [Epub ahead of print]. DOI:10. 1111/dom. 13804
13. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Estimands and sensitivity analysis in clinical trials E9 (R1) [Internet], 2017. Available from http://www. ich. org/fileadmin/Public_ Web_Site/ICH_Products/Guidelines/Efficacy/ E9 / E9-R1EWG_Step2 _Guideline_2017_0616. pdf. Accessed 14 November 2018
14. European Medicines Agency. Ozempic: Summary of Product Characteristics [Internet], 2018. Available from https://www. ema. europa. eu/ documents/product-information/ozempic-eparproduct-information_en. pdf. Accessed 14 November 2018
15. Bækdal TA, Borregaard J, Donsmark M, Breitschaft A, Søndergaard FL. Evaluation of the effects of water volume with dosing and post-dose fasting period on pharmacokinetics of oral semaglutide (Abstract) Diabetes 2017;66 (Suppl. 1):1179-P
16. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36: 1384-1395
17. Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biom J 2011;53:894-913
18. Little RJA, Rubin DB. Statistical Analysis With Missing Data. New York, NY, John Wiley and Sons, 1987
19. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 2017;5:251-260
20. Rosenstock J, Allison D, Birkenfeld AL, et al.; PIONEER 3 Investigators. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA 2019;321:1466-1480
21. Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA; LEADER Steering Committee; LEADER Trial Investigators. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial. Diabetes Care 2017;40:966-972
22. Nauck MA, Frossard JL, Barkin JS, et al. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care 2017;40:647-654
23. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 2012;18:472-477
24. Chen YH, Huang CN, Cho YM, et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, doubleblind, randomized, parallel-arm, active comparator, phase III trial. Diabetes Obes Metab 2018; 20:2121-2130
25. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017;19:524-536